• No results found

Cover Page The following handle holds various files of this Leiden University dissertation: http://hdl.handle.net/1887/81575

N/A
N/A
Protected

Academic year: 2021

Share "Cover Page The following handle holds various files of this Leiden University dissertation: http://hdl.handle.net/1887/81575"

Copied!
7
0
0

Bezig met laden.... (Bekijk nu de volledige tekst)

Hele tekst

(1)

Cover Page

The following handle holds various files of this Leiden University dissertation:

http://hdl.handle.net/1887/81575

Author: Tuin, K. van der

Title: Joining forces in endocrine cancer genetics: molecular testing, surveillance and

treatment decision making in clinical practice

(2)

JOINING FORCES IN

ENDOCRINE CANCER GENETICS

Molecular testing, surveillance and

treatment decision making

in clinical practice

(3)

ISBN: 978-94-6182-982-5

Cover design: K. van der Tuin and Off Page Layout and printing: Off Page, Amsterdam

The research presented in this thesis was performed at the Departments of Clinical Genetics and Pathology of Leiden University Medical Center, and was (partly) financially supported by the Children Cancer-free Foundation (KiKa, project number 265) and the Archer® International Research Challenge Grant

© 2019 Karin van der Tuin

(4)

JOINING FORCES IN ENDOCRINE CANCER GENETICS

Molecular testing, surveillance and treatment decision making

in clinical practice

Proefschrift

ter verkrijging van

de graad van Doctor aan de Universiteit Leiden, op gezag van Rector Magnificus prof.mr. C.J.J.M. Stolker,

volgens besluit van het College voor Promoties te verdedigen op donderdag 12 december 2019

klokke 16.15 uur

door

Karin van der Tuin

(5)

Promotores

Prof. Dr. H. Morreau

Prof. Dr. T.P. Links, Universitair Medisch Centrum Groningen Prof. Dr. F.J. Hes, Universitair Ziekenhuis Brussel, België

Leden promotiecommissie

Prof. Dr. A.M. Pereira

(6)

Chapter 1 General Introduction 7 Part I The role of molecular testing in endocrine cancer diagnostics and

treatment decision making

27 Chapter 2 Clinical and Molecular Characteristics May Alter Treatment Strategies

of Thyroid Malignancies in DICER1-syndrome

29 Chapter 3 Targetable Gene Fusions Identified in Radioactive Iodine-Refractory

Thyroid Carcinoma

53

Part II Identification of genetic predisposition in pediatric non-medullary thyroid carcinoma

65 Chapter 4 Germline Mutations in Predisposition Genes in Pediatric

Non-Medullary Thyroid Cancer

67

Part III Genetic counseling in endocrine tumor predisposition syndromes 81 Chapter 5 CDC73-Related Disorders: Clinical Manifestations and Case Detection

in Primary Hyperparathyroidism

83 Chapter 6 Clinical Aspects of SDHA-Related Pheochromocytoma and

Paraganglioma: A Nationwide Study

99 Chapter 7 A 93-year-old MEN2a Mutation Carrier Without Medullary Thyroid

Carcinoma: A Case Report and Overview of the Literature

115

Part IV General discussion 123

Chapter 8 Discussion and Future Perspectives 125

Chapter 9 Nederlandse Samenvatting 143

Appendix List of Publications 156

Authors and Affiliations 157

Genetic Glossary 160

List of Abbreviations 165

About the Author 167

PhD Portfolio 168

Dankwoord 1 7 1

(7)

Referenties

GERELATEERDE DOCUMENTEN

Panel 1, macroscopy hemi thyroidectomy right; Panel II and III, hematoxylin and eosin stain (HE) (×25 /×200) showing hyperplastic thyroid nodule with a somatic DICER1 RNase IIIb

Previous studies have relied mainly on candidate-gene approaches in selected patients, approaches which are, by design, limited. With the introduction of next-generation

Germline CDC73 analysis is recommended in individuals with (suspected) HPT-JT syndrome, familial isolated pHPT, atypical or malignant parathyroid histology, and young individuals

study we performed a nationwide evaluation of germline SDHA analyses undertaken in patients with PGL and characterized the clinical manifestations and disease penetrance in 30

We describe an unusual case of apparent non-penetrance in a 93-year-old carrier of an apparent de novo RET germline mutation (c.1858T>C, p.C620R) without clinical symptoms

With the introduction of next-generation sequencing (NGS), the last decades have seen remarkable advances in our understanding of the genetic contribution to disease. A growing list

en zo ja, kunnen we dat dan voorkomen?” Deze vragen zijn de motivatie voor de onderzoeken beschreven in dit proefschrift (hoofdstuk 2 t/m 7) naar de erfelijke aanleg voor

2015 Annual young Dutch Endocrine Meeting, Leiden, the Netherlands (2x oral presentation) 2015 Annual American Thyroid Association Meeting, victoria, Canada (poster presentation)